PIPE-307
We recently completed a randomized, double-blind, placebo-controlled, safety and tolerability, pharmacokinetic, single and multiple-ascending dose Phase 1 study of PIPE-307 in healthy volunteers enrolled at a single center in Australia.
In the second half of 2021 we completed a Phase 1, single-center, open-label, adaptive-design study to investigate the occupancy of brain M1R after a single oral dose of PIPE-307 in healthy volunteers by positron emission tomography (PET) using the radioligand [11C] PIPE-307.
